Dr. Reddy’s Laboratories (NYSE:RDY) Reaches New 12-Month Low – What’s Next?

Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) reached a new 52-week low during trading on Wednesday . The stock traded as low as $13.22 and last traded at $13.20, with a volume of 115167 shares changing hands. The stock had previously closed at $13.56.

Wall Street Analyst Weigh In

RDY has been the subject of several recent research reports. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. Finally, Barclays reduced their price target on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Stock Down 1.8 %

The company has a market capitalization of $11.11 billion, a P/E ratio of 21.20 and a beta of 0.50. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The stock’s fifty day moving average is $14.71 and its 200 day moving average is $15.26.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Research analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Large investors have recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Dr. Reddy’s Laboratories by 100.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 16,511 shares of the company’s stock worth $261,000 after acquiring an additional 8,262 shares during the period. Vident Advisory LLC lifted its position in shares of Dr. Reddy’s Laboratories by 535.5% in the 4th quarter. Vident Advisory LLC now owns 151,331 shares of the company’s stock worth $2,390,000 after purchasing an additional 127,518 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Dr. Reddy’s Laboratories during the 4th quarter valued at about $1,007,000. Two Sigma Advisers LP increased its position in shares of Dr. Reddy’s Laboratories by 254.8% during the fourth quarter. Two Sigma Advisers LP now owns 33,000 shares of the company’s stock valued at $521,000 after buying an additional 23,700 shares during the period. Finally, Thornburg Investment Management Inc. raised its stake in Dr. Reddy’s Laboratories by 232.3% in the fourth quarter. Thornburg Investment Management Inc. now owns 69,751 shares of the company’s stock worth $1,101,000 after buying an additional 48,763 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.